Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24122

Title:	Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
Authors:	Arnold, D. L. Barnett, M. Comi, G. Giovannoni, G. Pelletier, D. Rovira, A. Schippling, S. VAN WIJMEERSCH, Bart Margolin, D. H. Thangavelu, K. Traboulsee, A.
Issue Date:	2016
Publisher:	SAGE PUBLICATIONS LTD
Source:	MULTIPLE SCLEROSIS JOURNAL, 22(S3), p. 329-329 (Art N° P683)
Notes:	[Arnold, D. L.] NeuroRx Res, Montreal, PQ, Canada. [Arnold, D. L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada. [Barnett, M.] Univ Sydney, Sydney, NSW, Australia. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Giovannoni, G.] Queen Mary Univ London, Barts & London Sch Med, London, England. [Pelletier, D.] Univ Southern Calif, Los Angeles, CA USA. [Rovira, A.] Vall dHebron Univ Hosp, Barcelona, Spain. [Schippling, S.] Univ Zurich Hosp, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.] Sanofi Genzyme, Cambridge, MA USA. [Traboulsee, A.] Univ British Columbia, Vancouver, BC, Canada.
Document URI:	http://hdl.handle.net/1942/24122
ISSN:	1352-4585
e-ISSN:	1477-0970
ISI #:	000383267201422
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
10.1177@1352458516663081.pdf Restricted Access	Published version	389.97 kB	Adobe PDF	View/Open Request a copy

Check